News
LLY
732.20
-1.81%
-13.49
Scholz promises support for pharma sector in Germany as Merck invests
German Chancellor Olaf Scholz promises support for pharma sector in Germany as Merck invests. Merck is investing 1.5 billion euros in Germany. The drugmaker plans to use its life sciences Advanced Research Centre in Darmstadt. Germany has sought to improve conditions for the pharma and biotech sector.
Reuters · 3h ago
LLY vs. JNJ: Which Big Pharma Stock Is Better?
I evaluated two big pharma stocks, Eli Lilly and Johnson & Johnson, using TipRanks’ Comparison Tool. Shares of Eli Lilly have surged 26% year-to-date and are up 92% over the last 12 months. A neutral view for Eli Lilly suggests a bullish view for Johnson and Johnson. Eli Lilly is trading at a much higher valuation than JNJ.
TipRanks · 9h ago
Will Higher Keytruda Sales Drive Merck's Q1
NASDAQ · 11h ago
Plaintiffs' lawyers chosen to lead Ozempic litigation
Plaintiffs' lawyers chosen to lead Ozempic litigation. Lawsuits allege companies failed to warn of harsh side effects associated with diabetes and weight loss drugs. A judge appointed eight plaintiffs' lawyers to leadership roles in federal mass tort litigation. The companies have said the claims are meritless.
Reuters · 17h ago
Novo Nordisk comes under Senate probe over pricing for weight loss drugs
Danish drugmaker Novo Nordisk comes under Senate probe over pricing for weight loss drugs. Sen. Bernie Sanders says the company charges 'outrageously high prices' for the popular drug semaglutide in the U.S. The Senate committee wants to know how the company prices the drug.
Seeking Alpha · 17h ago
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senator Bernie Sanders wants to investigate Novo Nordisk A/S’s pricing strategies for diabetes and obesity medications. The Senate Committee on Health, Education, Labor, and Pensions is looking into the company's pricing discrepancies. Study suggests that Medicare may cover drugs approved for obesity and heart conditions.
Benzinga · 18h ago
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 20h ago
MEDIA-US Senate committee investigates Ozempic and Wegovy costs - NYT
Reuters · 21h ago
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
NASDAQ · 21h ago
3.6M Medicare patients could qualify for Wegovy coverage: report
Seeking Alpha · 22h ago
4 Large Drug Stocks to Hold on to Amid Industry Challenges
NASDAQ · 23h ago
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
NASDAQ · 23h ago
Artisan International Fund Q1 2024 Commentary
Seeking Alpha · 23h ago
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
NASDAQ · 23h ago
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
NASDAQ · 1d ago
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Eli Lilly's Zepbound is a weight-loss drug that brought in $175 million in its first few weeks on the market. The market for obesity drugs may reach more than $100 billion by 2030. But Medicare won't reimburse these drugs for weight loss alone. Lilly recently announced a new indication for the treatment in obese patients suffering from sleep apnea. This could open the door to reimbursement for these patients.
The Motley Fool · 1d ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
NASDAQ · 1d ago
JGRO: Promising ETF In The Growth Category
JPMorgan Active Growth ETF (JGRO) is an actively managed ETF focused on companies with above-average earnings growth. The portfolio is heavily invested in large companies of the technology, consumer discretionary and communication sectors. JGRO performance since inception is promising, slightly ahead of other growth funds in the same category.
Seeking Alpha · 1d ago
Madison Sustainable Equity Fund Q1 2024 Investment Strategy Letter
Equity markets had a solid start to the year, with the S&P 500 up 10.6%. The Madison Sustainable Equity Fund lagged the S-P 500 for the first quarter. The top contributors in the quarter were Eli Lilly, Apple, Target and Oracle Corporation.
Seeking Alpha · 1d ago
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Roche eyes return to growth after Q1 hit by forex, loss of COVID sales, strong Swiss franc. First-quarter sales fell by 6% to 14.4 billion Swiss francs, in line with expectations. Swiss drugmaker sees continued boost from eye drug Vabysmo. Reiterates 2024 guidance of sales growth in "mid single-digit" percentage range.
Reuters · 1d ago
More
Webull provides a variety of real-time LLY stock news. You can receive the latest news about Lilly Eli & Co through multiple platforms. This information may help you make smarter investment decisions.
About LLY
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.